Tech Company M&A Transactions
diaDexus Acquisition
diaDexus, operating out of South San Francisco, was acquired by VaxGen. What VaxGen paid for diaDexus was not disclosed.
Transaction Overview
Company Name
Acquired By
Announced On
4/15/2010
Transaction Type
M&A
Amount
Unknown
M&A Terms
If a definitive agreement to effect the merger is entered into and the merger is consummated, upon the closing of the transaction, based upon the current number of VaxGen common shares outstanding and the terms of the non-binding Summary of Terms, VaxGen will issue approximately 51.6 million shares of newly issued VaxGen common stock in exchange for all of diaDexus' outstanding equity. The number of shares of VaxGen common stock issued at the closing of the merger would not be subject to adjustment based on VaxGen's net cash, which is currently estimated to be approximately $28 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
343 Oyster Point Boulevard
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
diaDexus was formed in 1997 as a joint venture by SmithKline Beecham and Incyte. SmithKline Beecham granted diaDexus an exclusive license to certain diagnostic intellectual property, and Incyte contributed free access to its databases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Plewman
Chief Financial Officer
David Foster
Executive Vice President
Robert Wolfert
Browse more venture capital transactions:
Prev: 4/15/2010: Open English venture capital transaction
Next: 4/15/2010: The Grommet venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs